Genetic Variant Detection in Beta-Adrenergic Pathway for ROP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting genetic factors associated with severe retinopathies, such as retinopathy of prematurity (ROP), are inadequate, as they fail to identify specific genetic variants in molecular pathways like the ADRβ2 pathway, which are linked to the disease.
Innovation Solution
A method for detecting gene variants in the ADRβ pathway, including RAPGEF3, ADCY4, ADCY7, ADCY9, and PRKAR1A, by obtaining a sample from a subject, attaching adapters to free nucleic acids, amplifying the adapter-nucleic acids, and sequencing them to identify specific variants such as rs8082254, rs72847785, and rs2240079.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used, then the detection process is simple, but the ability to identify specific genetic variants in the ADRβ2 pathway is insufficient
Solution Approach 1:
The patent segments the detection process into multiple targeted steps: (1) obtaining biological samples, (2) extracting and preparing nucleic acids, (3) performing specific genetic variant detection in ADRβ2 pathway genes, and (4) analyzing results. This segmentation allows the method to focus on specific genetic variants (RAPGEF3, ADCY4, ADCY7, ADCY9, PRKAR1A) rather than attempting comprehensive genomic analysis, thereby improving detection precision for ROP-associated variants while managing complexity through a structured, stepwise approach.
2Loss of information
If comprehensive genetic analysis is performed, then more genetic factors can be identified, but the detection time and resource consumption increase
Solution Approach 1:
The patent extracts and focuses specifically on genetic variants within the ADRβ2 pathway genes (RAPGEF3, ADCY4, ADCY7, ADCY9, PRKAR1A) that are most strongly associated with ROP pathogenesis. By extracting only the relevant genetic information rather than performing whole-genome or exome sequencing, the method achieves sufficient information completeness for clinical decision-making while significantly reducing detection time and resource consumption compared to comprehensive genomic approaches.
Solution Approach 2:
The patent applies partial action by detecting only the specific genetic variants in the ADRβ2 pathway that have been proven to be strongly associated with ROP, rather than attempting to detect all possible genetic variants genome-wide. This partial detection strategy provides sufficient diagnostic information for clinical purposes while avoiding the excessive time and resource requirements of comprehensive genomic analysis.
3Reliability
If genetic variants are detected early, then targeted treatment can be implemented, but the complexity of genetic testing increases
Solution Approach 1:
The patent performs preliminary genetic testing for ADRβ2 pathway variants in newborns at high risk for ROP (premature infants, low birth weight, prolonged oxygen therapy). By conducting this targeted genetic analysis early in the clinical course, before severe retinopathy develops, the method enables preliminary identification of susceptible individuals who can then receive timely interventions such as intensified monitoring or preventive therapies, thereby improving treatment reliability while maintaining relatively simple testing protocols.
Data Source
AI summary
Described herein are methods for the identification and detection of genetic factors in the molecular pathways associated with vascular retinopathies or retinal diseases, for example mild, moderate or severe retinopathy of prematurity (ROP). Included herewith are methods of detecting genetic mutations associated with severe retinopathies, including factors in ADRβ2 pathways, which include RAPGEF3, ADCY7, ADCY9, PRKARIA, and ADCY4 variants. Further, this disclosure provides for methods of treating a subject having a detected genetic factor indicative of ROP.